{"name":"Perspective Therapeutics","slug":"perspective-therapeutics","ticker":"","exchange":"","domain":"perspective.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPcUNUUXNwaHV4WS1Za1FaWE5kOWREbG8yWDU3TzRJQVR1Z0JBOElqbXhUcDlGUXJLWmNWLTJ4VWNMV3lRTmRVN1JfUlJ2Wnp2ODVXZTZ4c2kyNzlxdHJyZXFibnV5TEo1bVZXTTZoNUYwTGVLWVFCVC1jbGVxXy04WjlKLWxjTF82M1pkLU1vdHBRNzlKWkVPOE9NMjF4VTZsM2p5NklVT2JaYUlvdm5oNzQwRkc5Qkw0aVdZTzBTRlQ5QjZyNS1yemFmR09FejZReDh6OG1hMkpFazRLMDZzbTY1WmZpQ01xMV9td3JFSjhmdndIemRBRWpPLXhGbTBNX1NIc29BT1dBa2dDMEdJbHNvZ3g2QWstdFptU2RMX05jYklzTVdEWDVLdFZQYk5UX2lJMkhWNkpJMGxD?oc=5","date":"2026-03-27","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQTm1acWJRYjEtZ2VBNEk2UlFoVzRnTjVKTHQ5QUlJTDBGM3JqY3JhMU9TeHlwa3diVDJsQkJtbVY5YkFtZGxGZktQOUgtUENmMGF0SHlERzVlVkc4Wm9vbFJJdnF1WnFDeng1ekJuamZoRHBWWFVKejc5RmVzTFc5d09TdU15dWNVZUVOVlBjNXo1TUlVMnExOV90YWtQNXdfMGQtQ0Ixa1BoN0RRVlFrTUhmTDVVY3J6YzFfTGI2elE0YmtqMGUyZlZfM3l4bFowbkc4dDllNFIyQVc1a3J6WnhqUTBLOXVIT1hRVW5CcWEwWjdSR3ZJc05jd1A?oc=5","date":"2026-03-16","type":"pipeline","source":"TMX Newsfile","summary":"Phio Pharmaceuticals Announces \"A Groundbreaking Approach to Treating Skin Cancer\" in a Fireside Chat with Force Family Office - TMX Newsfile","headline":"Phio Pharmaceuticals Announces \"A Groundbreaking Approach to Treating Skin Cancer\" in a Fireside Chat with Force Family ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQcUt6cS0zOURKbGtYaXptZElIai16MGhlaHExb29SME15ZmR3ZGpxbEZQa19ueUpkSkVZaU9haEI1LTNrRDlJS0xjLU9GMXZZd3ZvRVZrUkhIUFdJcS1ZNlh1Y0YzbHAwMnFZcWlsdWc1MkN6bGI0amVubjdDLVM0a3g0MjJ0TjhCT3llZUdsQjI2S0dpdGQw?oc=5","date":"2026-02-02","type":"pipeline","source":"Yahoo Finance","summary":"Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance","headline":"Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-30","type":"trial","source":"simplywall.st","summary":"Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans - simplywall.st","headline":"Why Perspective Therapeutics (CATX) Is Up 59.6% After New VMT-α-NET Trial Data And Expansion Plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQV0ZVaFVVTjZnRFB1eFNXTXhWNUV0YnA0YzhaNHZ0WlQ0U3lrV29oQWxtRzRXQlNpUDZ2Y2hncWw3Snk5d2ZxaFVvdnZ4cEVfNHNKejR4MHQ3UFRsNld2VVh5aVk2WVlJclV1ZnFNSThmNUN0ZU5waWxNZnZ1TFhqUDNsVkIzMkZ3REVfWUdQVDBHVkZFNzJB?oc=5","date":"2026-01-12","type":"pipeline","source":"Clinical Leader","summary":"Working (Successfully) With Pharma: A PAG's Perspective - Clinical Leader","headline":"Working (Successfully) With Pharma: A PAG's Perspective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOSDJkaHRVZzZLS0ZxSVp0bmN6VFpvQ0RiTEpqcGZIMjB3b3NvMkFFZ3hJRThxUF9JNkhGVkp0TGVpRkN3V1lEbVFTV1BUN0hRZ1Q5SVpXSEZlSUU0TTJoQTREa3k5TGxXY2VVaE96Y1E1NjYxMGVwZWMzTTYybXJDaVVkRkpNTnJWUnNVVFl4VHpveWpUaE1oY1ZrOHdIX3oySlB2WlNYanRvZnJSb2ZpazB3?oc=5","date":"2026-01-06","type":"pipeline","source":"Fierce Pharma","summary":"3 biopharma CEOs explain why they are 'authentically optimistic' for 2026 - Fierce Pharma","headline":"3 biopharma CEOs explain why they are 'authentically optimistic' for 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQNzhMdFVrVmdQRU1FSWp4OXlTc3JNdnZMVlBXdkN4OWZqa2wweGYwZXp2cV84VjNoTG90bVZ2OVVNdlFnejZlMHVEbmd1M01tNkROeTRzdnROUzN2aGRUYWFNamhaM29OY19VTFFlTkdMOFU3b3ZocmZfM3QxTS1VaXhIVEcwc0ZCZTU3MERfemRQeERtUjVPbkU1ZU1XV2JsQnVHNEVsdHE4SlNMZVE?oc=5","date":"2025-12-17","type":"pipeline","source":"pharmaphorum","summary":"ESMO25: Perspective on ‘inside-out oncology’ and targeted alpha radiotherapeutics - pharmaphorum","headline":"ESMO25: Perspective on ‘inside-out oncology’ and targeted alpha radiotherapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPeERyMW9yU1lKejRsMVZ5STQxWnctOTBPcG9zRUdDNzduWWdkZnRlR3lIWElmOFpncVVVTmRjbkxTR0RvRlU0cHZoX2VaT2htSmR1bjJhUzNtX3dmajBuckdUNXdDVDVBNDhIczYzWjBTd3FJLXJNWXZmcDFJM0tFQzZldHJXeUc2QXVvcTBId0JQZDJVUTFkd1pDYnYxVFFpVDVWUThxZHFveFVQSkRZX1J4OWpVRlJwbzNsb016NU5JSndSWFhiYVZ4OGYtNnc?oc=5","date":"2025-11-24","type":"pipeline","source":"Geneva Environment Network","summary":"Addressing Pharmaceuticals in the Environment through a Lifecycle Approach Event Series - Geneva Environment Network","headline":"Addressing Pharmaceuticals in the Environment through a Lifecycle Approach Event Series","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-21","type":"trial","source":"simplywall.st","summary":"Perspective Therapeutics (CATX): Assessing Valuation After ESMO Data Release and Sharp Share Price Drop - simplywall.st","headline":"Perspective Therapeutics (CATX): Assessing Valuation After ESMO Data Release and Sharp Share Price Drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQYjRhZ0dJRzktSHNtVllIb0dyUWZNS2ViTWFhaHpOQndfdmxyWE0xZGh6Nm9RQ011Qk1GQjZ2aWdUcFAzeXo5cVZUcm9VdDY0ZHQydmtRTzhwSE1mSkxIcEllRU5zRlRjZ0s2M25SdUJ3MkVGT0pvTEhBWlBRN25idC1EUVZhcjZFdW1URFoxcmFnMG10UWZsNHl6VjRTUElQS3ZoYUNLblFFTXk2NHpR?oc=5","date":"2025-10-07","type":"pipeline","source":"Contract Pharma","summary":"From Orphan Drugs to Advanced Therapies: Piramal’s Global R&D Perspective - Contract Pharma","headline":"From Orphan Drugs to Advanced Therapies: Piramal’s Global R&D Perspective","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE9Wa0hFcjVpSUhtNU5zVldybjRXNnlmV2FFeGU1UVlVUHJpNDA5OURXU1UzcW1MWGxndGkwcHVGdWxDTFpNQlR2S2xXcm45Tk1BX0Fsa2lxUV9TTE03MWMtdDNZdzFHN0RJcmpLeHNZUUU?oc=5","date":"2025-06-02","type":"regulatory","source":"Wiley Online Library","summary":"Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape - Wiley Online Library","headline":"Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}